This is an archive of papers published by the staff and faculty of Fox Chase Cancer Center. For questions about content, please contact Talbot Research Library
Last updated on
Mitchell MA , Johnson JE , Pascarelli K , Beeharry N , Chiourea M , Gagos S , Lev D , von Mehren M , Kipling D , Broccoli D
Doxorubicin Resistance in a Novel In vitro Model of Human Pleomorphic Liposarcoma Associated with Alternative Lengthening of Telomeres
Molecular Cancer Therapeutics. 2010 Mar;9(3) :682-692
AbstractSoft tissue sarcomas are a diverse set of fatal human tumors where few agents have demonstrable clinical efficacy, with the standard therapeutic combination of doxorubicin and ifosfamide showing only a 25% to 30% response rate in large multi-institutional trials. Although liposarcomas are the most common histologic form of adult soft tissue sarcomas, research in this area is severely hampered by the lack of experimentally tractable in vitro model systems. To this end, here we describe a novel in vitro model for human pleomorphic liposarcoma. The cell line (LS2) is derived from a pleomorphic liposarcoma that uses the alternative lengthening of telomeres (ALT) mechanism of telomere maintenance, which may be important in modulating the response of this tumor type to DNA-damaging agents. We present detailed baseline molecular and genomic data, including genome-wide copy number and transcriptome profiles, for this model compared with its parental tumor and a panel of liposarcomas covering multiple histologies. The model has retained essentially all of the detectable alterations in copy number that are seen in the parental tumor, and shows molecular karyotypic and expression profiles consistent with pleomorphic liposarcomas. We also show the utility of this model, together with two additional human liposarcoma cell lines, to investigate the relationship between topoisomerase 2A expression and the sensitivity of ALT-positive liposarcomas to doxorubicin. This model, together with its associated baseline data, provides a powerful new tool to develop treatments for this clinically poorly tractable tumor and to investigate the contribution that ALT makes to modulating sensitivity to doxorubicin. Mol Cancer Ther; 9(3); 682-92. (C) 2010 AACR.
NotesMitchell, Marcy A. Johnson, Jay E. Pascarelli, Kara Beeharry, Neil Chiourea, Maria Gagos, Sarantis Lev, Dina von Mehren, Margaret Kipling, David Broccoli, Dominique NIH [CA117675, CA 098987, CA006927]; Georgia Cancer Coalition ; Greek Secretariat of Research and Technology [05NON-EU-449]; National Cancer Institute Cancer Center Grant Support NIH grants CA117675 (J.E. Johnson), CA 098987 (D. Broccoli), and CA006927 (Fox Chase Cancer Center); Georgia Cancer Coalition; and Greek Secretariat of Research and Technology grant 05NON-EU-449 (S. Gagos and D. Broccoli). D. Broccoli is a Georgia Cancer Coalition Distinguished Cancer Scholar. The M. D. Anderson Cancer Center cell line characterization Core Facilities is supported by a National Cancer Institute Cancer Center Support Grant. 37 Amer assoc cancer research; 615 chestnut st, 17th floor, philadelphia, pa 19106-4404 usa 607go